{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:49:40Z","timestamp":1777294180788,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10620-018-5181-6","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T05:36:46Z","timestamp":1530250606000},"page":"2555-2563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Physicians\u2019 Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn\u2019s Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Christopher","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Ascoytia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly P.","family":"McCarrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"5181_CR1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324\u20131338.","journal-title":"Am J Gastroenterol"},{"key":"5181_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11938-018-0175-1","volume":"16","author":"M Duijvestein","year":"2018","unstructured":"Duijvestein M, Battat R, Vande Casteele N, D\u2019Haens GR, et al. Novel therapies and treatment strategies for patients with Inflammatory bowel disease. Curr Treat Options Gastroenterol. 2018;16:129\u2013146.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"5181_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ibd.20927","volume":"15","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler F, Fidder H, Ferrante M, Noman M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn\u2019s disease. Inflamm Bowel Dis. 2009;15:1295\u20131301.","journal-title":"Inflamm Bowel Dis"},{"key":"5181_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2009.09.056","volume":"138","author":"F Baert","year":"2010","unstructured":"Baert F, Moortgat L, Van Assche G, Caenepeel P, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn\u2019s disease. Gastroenterology. 2010;138:463\u2013468.","journal-title":"Gastroenterology"},{"key":"5181_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000347190","volume":"31","author":"G Rogler","year":"2013","unstructured":"Rogler G. Top-down or step-up treatment in Crohn\u2019s disease? Dig Dis. 2013;31:83\u201390.","journal-title":"Dig Dis"},{"key":"5181_CR6","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/S0140-6736(15)00068-9","volume":"386","author":"R Khanna","year":"2015","unstructured":"Khanna R, Bressler B, Levesque BG, Zou G, et al. Early combined immunosuppression for the management of Crohn\u2019s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386:1825\u20131834.","journal-title":"Lancet"},{"key":"5181_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","volume":"371","author":"G D\u2019Haens","year":"2008","unstructured":"D\u2019Haens G, Baert F, van Assche G, Caenepeel P, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial. Lancet. 2008;371:660\u2013667.","journal-title":"Lancet"},{"key":"5181_CR8","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/ajg.2011.50","volume":"106","author":"CN Bernstein","year":"2011","unstructured":"Bernstein CN, Nugent Z, Blanchard JF. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731\u2013736.","journal-title":"Am J Gastroenterol"},{"key":"5181_CR9","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/apt.12929","volume":"40","author":"AM Schoepfer","year":"2014","unstructured":"Schoepfer AM, Bortolotti M, Pittet V, Mottet C, et al. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;40:930\u2013937.","journal-title":"Aliment Pharmacol Ther"},{"key":"5181_CR10","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.crohns.2012.09.001","volume":"7","author":"EI Benchimol","year":"2013","unstructured":"Benchimol EI, Cook SF, Erichsen R, Long MD, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:878\u2013889.","journal-title":"J Crohns Colitis"},{"key":"5181_CR11","first-page":"456","volume":"30","author":"P Holko","year":"2017","unstructured":"Holko P, Kawalec P, Stawowczyk E. Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012\u20132014: an analysis of nationwide databases. Eur J Gastroenterol Hepatol. 2017;30:456\u2013464.","journal-title":"J Crohns Colitis"},{"key":"5181_CR12","doi-asserted-by":"publisher","first-page":"P485","DOI":"10.1093\/ecco-jcc\/jjx180.612","volume":"12","author":"K Paridaens","year":"2018","unstructured":"Paridaens K, Yip YL, Ghatnekar O, Plassais M, et al. Real-world evidence (RWE) on outcomes and clinical treatment patterns of 5-aminosalicylic acid (5-ASA) in mild Crohn\u2019s disease (CD) from European healthcare databases (the CROHN\u2019S investigation). J Crohns Colitis. 2018;12:P485.","journal-title":"J Crohns Colitis"},{"key":"5181_CR13","first-page":"CD003715","volume":"9","author":"AK Akobeng","year":"2016","unstructured":"Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2016;9:CD003715.","journal-title":"Cochrane Database Syst Rev"},{"key":"5181_CR14","first-page":"CD00887","volume":"7","author":"WC Lim","year":"2016","unstructured":"Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Syst Rev. 2016;7:CD00887.","journal-title":"Syst Rev"},{"key":"5181_CR15","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2174\/1389450115666140908125738","volume":"15","author":"S Danese","year":"2014","unstructured":"Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn\u2019s disease. Curr Drug Targets. 2014;15:1056\u20131063.","journal-title":"Curr Drug Targets"},{"key":"5181_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/gut.51.4.536","volume":"51","author":"RA Ransford","year":"2002","unstructured":"Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536\u2013539.","journal-title":"Gut"},{"key":"5181_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19:349\u2013357.","journal-title":"Int J Qual Health Care"},{"key":"5181_CR18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","volume":"77","author":"RW Summers","year":"1979","unstructured":"Summers RW, Switz DM, Sessions JT Jr, Becktel JM, et al. National Cooperative Crohn\u2019s Disease Study: results of drug treatment. Gastroenterology. 1979;77:847\u2013869.","journal-title":"Gastroenterology"},{"key":"5181_CR19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","volume":"86","author":"H Malchow","year":"1984","unstructured":"Malchow H, Ewe K, Brandes JW, Goebell H, et al. European Cooperative Crohn\u2019s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249\u2013266.","journal-title":"Gastroenterology"},{"key":"5181_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","volume":"104","author":"JW Singleton","year":"1993","unstructured":"Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, et al. Mesalamine capsules for the treatment of active Crohn\u2019s disease: results of a 16-week trial. Pentasa Crohn\u2019s Disease Study Group. Gastroenterology. 1993;104:1293\u20131301.","journal-title":"Gastroenterology"},{"key":"5181_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomollon","year":"2017","unstructured":"Gomollon F, Dignass A, Annese V, Tilg H, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3\u201325.","journal-title":"J Crohns Colitis"},{"key":"5181_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/ecco-jcc\/jjw144","volume":"11","author":"AL Hart","year":"2017","unstructured":"Hart AL, Lomer M, Verjee A, Kemp K, et al. What Are the top 10 research questions in the treatment of inflammatory bowel disease? A priority setting partnership with the James Lind Alliance. J Crohns Colitis. 2017;11:204\u2013211.","journal-title":"J Crohns Colitis"},{"key":"5181_CR23","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of G. Management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2009;104:465\u2013483.","journal-title":"Am J Gastroenterol"},{"key":"5181_CR24","first-page":"702","volume":"147","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ. Crohn\u2019s disease evaluation and treatment: clinical decision tool Gastroenterology. 2014;147:702\u2013705.","journal-title":"Crohn\u2019s disease evaluation and treatment: clinical decision tool Gastroenterology"},{"key":"5181_CR25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","volume":"19","author":"WJ Tremaine","year":"1994","unstructured":"Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn\u2019s colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278\u2013282.","journal-title":"J Clin Gastroenterol"},{"key":"5181_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","volume":"2","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn\u2019s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379\u2013388.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5181_CR27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1542-3565(04)00121-1","volume":"2","author":"BG Feagan","year":"2004","unstructured":"Feagan BG. 5-ASA therapy for active Crohn\u2019s disease: old friends, old data, and a new conclusion. Clin Gastroenterol Hepatol. 2004;2:376\u2013378.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5181_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/ecco-jcc\/jjx171","volume":"12","author":"V Jairath","year":"2018","unstructured":"Jairath V, Hokkanen S, Guizzetti L, Boxall N, Campbell-Hill S, Patel H. 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015: a UK population-based study. J Crohns Colitis. 2018;12:405.","journal-title":"J Crohns Colitis"},{"key":"5181_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","volume":"117","author":"MD Silverstein","year":"1999","unstructured":"Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, et al. Clinical course and costs of care for Crohn\u2019s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49\u201357.","journal-title":"Gastroenterology"},{"key":"5181_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2040622314563929","volume":"6","author":"R Peluso","year":"2015","unstructured":"Peluso R, Manguso F, Vitiello M, Iervolino S, Di Minno MN. Management of arthropathy in inflammatory bowel diseases. Ther Adv Chronic Dis. 2015;6:65\u201377.","journal-title":"Ther Adv Chronic Dis"},{"key":"5181_CR31","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1136\/gut.2005.070896","volume":"54","author":"TP Staa van","year":"2005","unstructured":"van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573\u20131578.","journal-title":"Gut"},{"key":"5181_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/bmj.315.7107.520","volume":"315","author":"J Cockburn","year":"1997","unstructured":"Cockburn J, Pit S. Prescribing behaviour in clinical practice: patients\u2019 expectations and doctors\u2019 perceptions of patients\u2019 expectations: a questionnaire study. BMJ. 1997;315:520\u2013523.","journal-title":"BMJ"},{"key":"5181_CR33","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2753.2007.00901.x","volume":"14","author":"E Lado","year":"2008","unstructured":"Lado E, Vacariza M, Fernandez-Gonzalez C, Gestal-Otero JJ, Figueiras A. Influence exerted on drug prescribing by patients\u2019 attitudes and expectations and by doctors\u2019 perception of such expectations: a cohort and nested case-control study. J Eval Clin Pract. 2008;14:453\u2013459.","journal-title":"J Eval Clin Pract"},{"key":"5181_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/apt.13460","volume":"43","author":"CA Siegel","year":"2016","unstructured":"Siegel CA, Horton H, Siegel LS, Thompson KD, et al. A validated web-based tool to display individualised Crohn\u2019s disease predicted outcomes based on clinical, serologic and genetic variables. Aliment Pharmacol Ther. 2016;43:262\u2013271.","journal-title":"Aliment Pharmacol Ther"},{"key":"5181_CR35","doi-asserted-by":"publisher","first-page":"P493","DOI":"10.1093\/ecco-jcc\/jjx161","volume":"12","author":"KJ Kim","year":"2018","unstructured":"Kim KJ, Kwak MS, Soh JS, Cho DH, et al. Adding 5-aminosalicylate to immunomodulators showed no additional benefit in Crohn\u2019s disease. J Crohns Colitis. 2018;12:P493.","journal-title":"J Crohns Colitis"},{"key":"5181_CR36","doi-asserted-by":"publisher","first-page":"P363","DOI":"10.1093\/ecco-jcc\/jjx180.490","volume":"12","author":"B Limketkai","year":"2018","unstructured":"Limketkai B, Ungaro R, Jess T, Allin K, et al. Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomes. J Crohns Colitis. 2018;12:P363.","journal-title":"J Crohns Colitis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5181-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T19:19:14Z","timestamp":1561749554000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5181-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["5181"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5181-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,29]]},"assertion":[{"value":"4 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Christopher Ma has no conflicts of interest to declare. Carla Ascoytia, Kelly McCarrier, and Mona Martin are employed by Health Research Associates (HRA). HRA received funding to conduct the interviews and analyze the qualitative data but the authors have no additional individual conflicts of interest to declare. Brian Feagan has received grant\/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor Inc., Elan\/Biogen, UCB Pharma, Bristol-Myers Squibb, Genentech, ActoGenix, and Wyeth Pharmaceuticals Inc.; consulting fees from Millennium Pharmaceuticals, Merck, Centocor Inc., Elan\/Biogen, Janssen-Ortho, Teva Pharmaceuticals, Bristol-Myers Squibb, Celgene, UCB Pharma, AbbVie, Astra Zeneca, Serono, Genentech, Tillotts Pharma AG, Unity Pharmaceuticals, Albireo Pharma, Given Imaging Inc., Salix Pharmaceuticals, Novo Nordisk, GSK, Actogenix, Prometheus Therapeutics and Diagnostics, Athersys, Axcan, Gilead, Pfizer, Shire, Wyeth, Zealand Pharma, Zyngenia, GiCare Pharma Inc., and Sigmoid Pharma; and speaker\u2019s fees from UCB, AbbVie, and J&J\/Janssen. Vipul Jairath has received consulting fees from AbbVie, Sandoz, Takeda, Janssen, Robarts Clinical Trials; speaker\u2019s fees from Takeda, Janssen, Shire, Ferring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}